Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company, announced that Denali Capital Acquisition Corp. filed a Registration Statement on Form S-4 with the Securities and Exchange Commission (SEC).
This filing pertains to the previously announced proposed Business Combination between Semnur and Denali. The Registration Statement includes a preliminary proxy statement/prospectus, providing important information about the transaction.
The filing represents a significant regulatory milestone in the process of the business combination, which is expected to unlock value from the Semnur asset for Scilex shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.